Benefits
May Improve Mental Health
Folate plays a role in neurotransmitter production, and low levels are linked to depression and cognitive decline. Some studies suggest folate supplements may support mood and cognitive function, particularly in those with deficiency.
Potential Cancer Risk Reduction
Adequate folate may lower the risk of certain cancers (e.g., colorectal) by supporting DNA repair. However, excessive folic acid intake might promote tumor growth in some cases, so moderation is key.
Aids in Fertility
Folate supports reproductive health in both men and women by improving sperm quality and ovulation, potentially enhancing fertility outcomes.
Supports DNA Synthesis and Cell Division
Folate is critical for DNA and RNA production, making it essential for cell growth and repair. This is especially important during periods of rapid growth, such as pregnancy or infancy.
Prevents Neural Tube Defects in Pregnancy
Folate supplementation (often as folic acid) is widely recommended for pregnant women or those planning pregnancy. It significantly reduces the risk of neural tube defects like spina bifida in developing fetuses. The recommended dose is typically 400–800 mcg daily for women of childbearing age.
Reduces Risk of Anemia
Folate aids in red blood cell production. Deficiency can lead to megaloblastic anemia, characterized by large, immature red blood cells. Supplementation helps correct this, improving energy and oxygen transport.
Supports Heart Health
Folate helps lower homocysteine levels, an amino acid linked to heart disease when elevated. By reducing homocysteine, folate may decrease the risk of cardiovascular issues, though evidence on direct heart disease prevention is mixed.
Mechanism of action
DNA and RNA Synthesis
Folate, as THF, donates one-carbon units in the synthesis of purines and pyrimidines, the building blocks of DNA and RNA. Specifically, it supports the conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (TMP), a key step in DNA synthesis, catalyzed by the enzyme thymidylate synthase. This is crucial for cell division and growth, particularly in rapidly dividing cells like those in bone marrow, skin, or the developing fetus.
Methylation Reactions
Folate is integral to the methionine cycle, where 5-methyltetrahydrofolate (5-MTHF) donates a methyl group to homocysteine, converting it to methionine via the enzyme methionine synthase, with vitamin B12 as a cofactor. Methionine is then converted to S-adenosylmethionine (SAM), the primary methyl donor for DNA, RNA, proteins, and lipid methylation, influencing gene expression and epigenetic regulation.
Homocysteine Metabolism
By facilitating the conversion of homocysteine to methionine, folate helps prevent the accumulation of homocysteine, high levels of which are associated with cardiovascular disease and neurological issues.
Red Blood Cell Formation
Folate supports erythropoiesis (red blood cell production) by enabling DNA synthesis in developing red blood cells. Deficiency can lead to megaloblastic anemia, characterized by large, immature red blood cells.
Antioxidant and Cellular Protection
Folate indirectly supports cellular health by maintaining proper methylation and reducing oxidative stress, which can protect against DNA damage and related diseases.
Clinical trials
Folic Acid and Carotid Intima-media Thickness (FACIT) trial: 3-year, randomized, double-blind, placebo-controlled trial of 800 µg/day folic acid vs placebo in 818 older adults (50-70 years) with elevated homocysteine. Outcomes: cognitive function, atherosclerosis markers. (Lancet)
818 older adults with elevated homocysteine. 3-year intervention.
Folic acid significantly improved memory, information processing speed, and sensorimotor speed vs placebo over 3 years. Reduced plasma homocysteine ~26%. Important positive finding for folate-elevated homocysteine populations. Note: subsequent trials in normal-homocysteine populations have been less impressive — folate cognitive benefits may be limited to those with elevated homocysteine.
Folic Acid Clinical Trial (fact): randomized, double-blind, placebo-controlled, Phase III trial of folic acid (4 mg/day) vs placebo for prevention of pre-eclampsia in pregnant women at increased risk. (Wen et al. 2018, BMJ)
2,464 high-risk pregnant women.
Primary endpoint negative: high-dose folic acid did not reduce pre-eclampsia rates vs placebo in high-risk pregnant women. Important negative finding that contradicts earlier observational suggestions. Critical context: this does not diminish the established benefit of pre-conception folic acid for neural tube defect prevention (400-800 µg/day starting 1 month before conception); the fact trial specifically tested high-dose folic acid for pre-eclampsia, which was not supported.
FolATED trial: double-blind, placebo-controlled, randomized trial in three Wales centers examining folic acid 5 mg/day as augmentation to antidepressants in major depression. (Health Technol Assess)
Adults with major depressive disorder on antidepressant therapy.
Folic acid augmentation did not significantly improve depression outcomes vs placebo augmentation. Important negative finding. Note: methylated folate (L-5-MTHF / Metafolin®) for depression augmentation has shown more promise in subsequent trials, particularly for MTHFR-deficient patients — but standard folic acid does not appear to augment antidepressants overall.
Randomized controlled trial in 152 elderly Chinese participants with mild cognitive impairment receiving folic acid (400 µg/day) vs placebo for 12 months. Outcomes: cognitive function, inflammatory cytokines. (Ma et al. 2016, Sci Rep)
152 elderly with MCI in Tianjin, China. 12-month intervention.
Folic acid improved cognitive function scores and reduced inflammatory cytokines vs placebo. Adds evidence for folate in MCI in populations with potentially marginal folate status. Note: results may differ in folate-fortified populations (US/Canada have mandatory grain folate fortification).
Single-blind pilot clinical trial in 30 healthy individuals in Australia comparing absorption of three folate forms: folic acid, L-5-methyltetrahydrofolate (L-5-MTHF / Metafolin®), and folinic acid. Outcome: serum and RBC folate levels.
30 healthy adults.
L-5-MTHF showed superior plasma folate elevation vs folic acid in some MTHFR genotypes. Folic acid requires conversion to L-5-MTHF via DHFR (limited capacity in humans) and MTHFR (677TT genotype reduces conversion ~70%). Suggests L-5-MTHF may be preferable for individuals with reduced MTHFR activity. Note: at typical supplemental doses (≤400 µg), most healthy individuals tolerate folic acid adequately.
Clinical trial investigating folic acid supplementation for secondary prevention of cardiovascular events in patients with established CVD. (J Am Coll Cardiol — Goes & TPI; or related)
Patients with established CVD.
Folic acid lowered homocysteine but did not reduce cardiovascular events. Important negative finding consistent with the broader homocysteine-lowering trial literature (HOPE-2, NORVIT, VISP — all largely negative for hard CV events).
Double-blind, multicenter clinical trial (NEJM) in 636 patients undergoing coronary stenting receiving folic acid (1 mg/day) + B12 + B6 vs placebo. Outcomes: in-stent restenosis at 6 months.
636 post-coronary-stent patients.
Paradoxical finding: B-vitamin supplementation increased restenosis risk vs placebo (HR 1.34, p=0.05). Authors concluded folate-B12-B6 should not be used post-stenting. Critical context: this and several other trials showed homocysteine lowering does not improve CV outcomes and may even worsen them in specific contexts. Influential paper that helped end enthusiasm for B-vitamin CV prevention.
NORVIT trial: large clinical trial (n=3,749) testing folate (0.8 mg/day) ± vitamin B12 ± vitamin B6 for cardiovascular event prevention in patients post-myocardial infarction. (Bønaa et al. 2006, NEJM)
3,749 post-MI patients.
Folate + B12 ± B6 did not reduce recurrent CV events. The folate + B12 + B6 arm showed a trend toward increased events (combined endpoint HR 1.22, p=0.05). Combined with HOPE-2 and, NORVIT effectively ended the homocysteine hypothesis as a CV intervention target. Note: this does not diminish folate's established role in neural tube defect prevention or anemia treatment.